Botanix Pharmaceuticals Limited engages in the research and development of dermatology and antimicrobial products in Australia and the United States. Its product pipeline includes Sofpironium Bromide, a drug in development for the treatment of primary axillary hyperhidrosis that has completed Phase 3 clinical programs; BTX 1503, a transdermal gel formulation for the treatment of serious acne in adults and teenagers that has completed Phase II clinical trials; BTX 1801, which has completed Phase IIa clinical trials for the treatment of staphylococcus aureus and methicillin resistant staphylococcus aureus; BTX 1702 that is in Phase II clinical trials for the treatment of papulopustular rosacea; and BTX 1204A for the treatment of atopic dermatitis. Botanix Pharmaceuticals Limited was incorporated in 1984 and is based in West Perth, Australia.
Metrics to compare | BOT | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipBOTPeersSector | |
---|---|---|---|---|
P/E Ratio | −15.5x | −3.4x | −0.5x | |
PEG Ratio | 0.08 | −0.01 | 0.00 | |
Price/Book | 6.6x | 1.9x | 2.6x | |
Price / LTM Sales | 293.8x | 7.6x | 3.0x | |
Upside (Analyst Target) | 273.1% | 269.6% | 49.2% | |
Fair Value Upside | Unlock | 14.8% | 7.4% | Unlock |